Product image of Nalador (Sulprostone) supplied by GNH India

Nalador

Active Ingredient:
Sulprostone
Origin:
EU

Nalador (Sulprostone)

Sulprostone, the active ingredient in Nalador, is a prostaglandin E2 analog presented as an intravenous solution for intravenous use. It acts as a uterotonic and gastroprotective agent, employed to induce labor, treat gastric ulcer disease, and prevent gastric lesions associated with NSAID therapy.

GNH India supplies Nalador as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. The company provides quality‑assured products to healthcare institutions across multiple continents, ensuring reliable supply chains and compliance with Good Distribution Practice.

Manufacturer / TM Owner

Teofarma S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Sulprostone is a prostaglandin E2 analog used in obstetric and gastroenterology settings to modulate uterine activity and enhance gastric mucosal defense.

  • Induction of labor: facilitates uterine contractions to initiate childbirth.
  • Gastric ulcer treatment: promotes gastric mucosal protection and healing of ulcer lesions.
  • Prevention of NSAID‑induced gastric lesions: reduces risk of gastric injury in patients receiving non‑steroidal anti‑inflammatory drugs.

How It Works

  • Sulprostone acts as an agonist at prostaglandin E2 (EP) receptors, primarily EP1‑EP4 subtypes. Activation of EP receptors on uterine smooth muscle raises intracellular calcium, producing strong uterine contractions that aid labor induction. In the gastrointestinal tract, EP receptor stimulation enhances mucus and bicarbonate secretion, improves mucosal blood flow, and inhibits acid secretion, thereby strengthening gastric mucosal protection and promoting ulcer healing.

Side Effects

Sulprostone may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate feeling of sickness.
  • Vomiting: occasional episodes.
  • Diarrhea: loose stools.
  • Uterine hyperstimulation: excessive uterine contractions.
  • Flushing: transient skin redness.

Serious or Rare Side Effects

  • Severe hypotension: marked drop in blood pressure.
  • Pulmonary edema: fluid accumulation in the lungs.
  • Allergic reactions: anaphylaxis, rash, or angioedema.

Precautions & Warnings

When using Sulprostone, clinicians should observe specific precautions to minimize risks and ensure safe administration.

  • Patient assessment: evaluate cardiovascular status and uterine activity before infusion.
  • Contraindications: avoid in patients with known hypersensitivity to prostaglandins or severe cardiac disease.
  • Monitoring: continuously monitor blood pressure, heart rate, and uterine contraction pattern during treatment.
  • Drug interactions: review concomitant medications that may affect prostaglandin pathways or hemodynamics.
  • Use in pregnancy: limit to obstetric indications under specialist supervision, considering fetal monitoring.
  • Store at ambient temperature: keep below 25°C, protect from light and moisture, and retain in original container.

Avoid Interactions

Sulprostone can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • NSAIDs: may reduce gastroprotective effect and increase risk of gastric injury.
  • Antihypertensives: additive hypotensive effect, leading to significant blood pressure drop.
  • Oxytocin: combined uterotonic action may cause uterine hyperstimulation.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: increased bleeding risk due to mucosal irritation.
  • Diuretics: may enhance hypotensive response.
  • Beta‑blockers: may blunt compensatory heart rate increase during hypotension.

Frequently Asked Questions

Nalador contains sulprostone, which is employed as a uterotonic to induce labor and as a gastroprotective agent to treat gastric ulcers and to prevent gastric lesions that can occur with non‑steroidal anti‑inflammatory drug therapy.

Sulprostone binds to prostaglandin E2 (EP) receptors, stimulating uterine smooth‑muscle contraction and enhancing gastric mucosal defenses by increasing mucus and bicarbonate secretion, improving blood flow, and reducing gastric acid output.

The dosing regimen for Nalador is determined by the prescribing clinician based on the specific indication, patient condition, and local guidelines. Exact dose and infusion rate should be individualized and documented by the healthcare professional.

Sulprostone is used during pregnancy for labor induction under specialist supervision, but its safety profile requires careful fetal monitoring. Limited data are available for breastfeeding; the decision to continue treatment should be made by the prescriber after weighing potential benefits and risks.

To request Nalador, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

The primary alternative to sulprostone is dinoprostone, another prostaglandin E2 analog. Both agents induce uterine contractions, but sulprostone has a shorter half‑life and may produce a more rapid onset of action, while dinoprostone is often available in oral or vaginal formulations.

Nalador should be stored at ambient temperature, below 25 °C, protected from light and moisture, and kept in its original packaging. Avoid freezing the solution and ensure the container is sealed to maintain sterility until use.

Nalador is supplied as an intravenous solution and is administered by slow IV infusion under continuous clinical monitoring. The infusion rate and total volume are set by the treating physician according to the therapeutic goal.

Serious adverse events include severe hypotension, uterine hyperstimulation leading to fetal distress, pulmonary edema, and rare allergic reactions such as anaphylaxis. Prompt recognition and supportive measures are essential if these events occur.

Nalador is contraindicated in patients with known hypersensitivity to sulprostone or other prostaglandins, those with severe cardiac disease, uncontrolled hypertension, or active severe bleeding. It should also be avoided in women with a history of uterine rupture or in settings where labor induction is not indicated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sulprostone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT